Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …

Background: Compelling evidence shows that progestins regulate breast cancer growth.
Using preclinical models, we demonstrated that antiprogestins are inhibitory when the level …

PURPOSE Mifepristone (RU486) is a progesterone receptor (PgR) antagonist that has been
shown to be active in some preclinical hormone-dependent breast cancer tumor models and …

Background Mifepristone (MF) has been largely used in reproductive medicine due to its
capacity to modulate the progesterone receptor (PR). The study of MF has been expanded …

The search for active and safe alternatives to current systemic therapies is one of the main
objectives of current breast cancer research. Over the last three decades since the discovery …

Background Glucocorticoid receptor (GR) activity has been associated with chemotherapy
resistance and poor outcomes in patients with triple negative breast cancer (TNBC). The aim …

BACKGROUND Progestins as well as estrogens have a role in breast cell proliferation and
the development of breast cancer. Here, the effect of mifepristone on cell proliferation in …

Introduction Patients with various advanced cancers devoid of nuclear progesterone
receptors (nPR) have demonstrated increased quality and length of life when treated with …

Mifepristone treatment for advanced cancer has demonstrated considerable improvement in
both length and quality of life in patients who no longer have any other treatment options …

There is emerging interest in understanding the role of progesterone receptors (PRs) in
breast cancer. The aim of this study was to investigate the proliferative effect of progestins …